Background. To achieve fair-coverage decision making, both material criteria and criteria of procedural justice have been proposed. The relationship between these is still unclear. Objective. To analyze hypotheses underlying the assumption that more assessment, transparency, and participation have a positive impact on the reasonableness of coverage decisions. Methods. We developed a structural equation model in which the process components were considered latent constructs and operationalized by a set of observable indicators. The dependent variable ''reasonableness'' was defined by the relevance of clinical, economic, and other ethical criteria in technology appraisal (as opposed to appraisal based on stakeholder lobbying). We conducted an Internet survey among conference participants familiar with coverage decisions of third-party payers in industrialized countries between 2006 and 2011. Partial least squares path modeling (PLS-PM) was used, which allows analyzing small sample sizes without distributional assumptions. Data on 97 coverage decisions from 15 countries and 40 experts
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Conceptual frameworks describing key elements of coverage decision processes typically distinguish between assessment and appraisal. [5] [6] [7] [8] In the assessment step, potential outcomes are analyzed to extract information about a product's effectiveness and costs or cost-effectiveness. In the appraisal step, the desirability of assessed outcomes is judged through definition of criteria, which are based on the values of the individual or committee that decides on the technology. Further elements that are frequently incorporated in conceptual frameworks are the exchange of information and stakeholder participation. 2, 4, 9 Given the complexity of decision processes, a large number of further process elements can be included in the analysis, as has been done by Hutton and others. 10 Given the time constraints of respondents, surveys have to restrict the assessed items to a small number that can be justified theoretically and surveyed empirically.
From the viewpoint of ethical theory, both material and procedural criteria have been proposed to guide legitimate decision making about scarce health care resources. The material criteria typically include a technology's clinical effectiveness, economic criteria such as cost-effectiveness, and other ethical criteria such as severity of disease or equal access. 11, 12 Therefore, both the criteria relevant in appraisal, as well as the generation of evidence about to what extent a technology meets the criteria of effectiveness and cost-effectiveness, appear to be important in the analysis of coverage decision processes from an ethical perspective.
A frequently cited procedural framework is ''accountability for reasonableness'' by Daniels and Sabin. 13 Given that reasonable people may disagree about which material criteria should determine the decision outcome, they only postulate that the decision should be based on evidence and appraisal criteria, which ''all fair-minded parties (managers, clinicians, patients, and consumers in general) can agree are relevant to deciding how to meet the diverse needs of a covered population under necessary resource constraints.'' 13 As a complement, they propose transparency and participation in the minimum form of a ''mechanism for challenge and dispute resolution . . ., including the opportunity for revising decisions in light of further evidence or arguments.'' 13 The framework has been criticized for demanding too little participation to achieve truly legitimate decision outcomes in the absence of a specification of material criteria. 14 The question of how much transparency or participation is desirable is thus an unresolved issue. 15 A recent economic theory of the fourth hurdle provides a theoretical framework to address assessment, appraisal, transparency, and participation in one common framework. 9 It interprets procedural criteria as a means to promote material ones: transparency and participation can be seen as investments to ensure that decisions are indeed oriented at the value judgments of the covered population rather than on the opportunistic preferences of their decision-making agents. These investments are justified on economic grounds if the expected costs of increased transparency and participation fall below the expected costs associated with the agency problems. Investments in evidence generation can be judged by similar criteria 16 : here, the value of reducing decision uncertainty can be compared with the costs of evidence generation. 9 Both the considerations from ethical and economic theory are based on the assumption that more assessment, transparency, and participation have an impact on decision making and that this association is considered positive. Given the complexity of decision problems and the values that are reflected in each decision, 6 neither the ethical nor the economic frameworks provide a standardized characterization of ''good'' decisions. Instead, they refer to reasonable medical, economic, and other ethical criteria. It is empirically unclear, though, to what extent this is indeed the case.
Empirical research has addressed various aspects of coverage decision processes but barely incorporated theoretical considerations. 17 Studies that analyzed real-world decisions focused on influences on decision outcomes by cost-effectiveness considerations and the quality of the available evidence, analysis of single criteria, and committees and selected process characteristics such as the timing after market authorization.
The objective of our study is to extend this work and analyze hypotheses on the relation between process components and the use of reasonable appraisal criteria in decision making on health technologies. We state a structural equation model (SEM), which we estimated with partial least squares path modeling as the modeling technique using data on realworld decisions from industrialized countries.
METHODS

Definition of Concepts and Hypotheses
Our hypotheses are based on the following 4 components that have been discussed in the context of evidence-based decision making, as well as procedural and distributive justice.
Transparency (h 1 ): Processes are considered transparent if relevant information is provided so that decisions can be retraced. 18, 19 More transparency improves the extent to which a decision can be controlled. Transparency is reflected by the volume of documentation available for a decision and the degree of detail in the documentation of processes and decision outcomes. 18, 20, 21 Participation (h 2 ): Participation implies that different stakeholder groups are involved at various stages of decision processes to ensure that their interests are not neglected. Stakeholder groups may include manufacturers, patients, or government or service providers. Involvement may be in the form of providing information, commenting, appealing, or voting. 20, [22] [23] [24] [25] Scientific rigor (of assessment) (h 3 ): The assessment stage has been characterized by methods that ground on evidence-based medicine, comparative effectiveness research, and health technology assessment (HTA) to make statements about the technology's effectiveness and cost-effectiveness. 26, 27 The information that is produced depends on the development stage of the product and the assessment requirements stated by decision makers. 4, 20 Assessments depend on scientific judgments about the exact evaluation methods used for a technology. Thus, scientific rigor may vary across decisions and committees due to variation in methods and level of evidence. We defined scientific rigor by the methodological standards for generating evidence. The assessment of effectiveness may range from collecting expert opinions to quantitative metaanalyses of studies. Assessment of costs may go from rough estimates to comprehensive cost-effectiveness or budget impact analyses. Rigorous assessments are prerequisites to reasonable decisions that are evidence based and accepted by informed people. 18, 19 Reasonableness (h 4 ): Technology appraisal involves value judgments about the technology. The criteria used in technology appraisal have been addressed by a large body of theoretical and empirical research. 11, 12, [28] [29] [30] [31] [32] [33] They can be selected implicitly, ad hoc, history based, or as a result of priority-setting exercises. 2, 4, 28, 29 It is frequently argued that in a pluralistic society, there is not one single criterion but a set of criteria. 11, 12 Thus, reasonableness is difficult to operationalize because what is considered reasonable depends on potentially varying value judgments of decision makers and stakeholders as well as the situation. In this model, we propose to use the extent to which typically accepted criteria are considered in technology appraisal: the use of clinical, economic, and other ethical considerations (as opposed to the role of lobby interests of stakeholders). 2, 30, 34 Although we neither weigh the criteria nor predefine a certain combination, we assume that the higher the relevance of each criterion considered, the stronger the degree of reasonableness is reflected.
We considered the components participation, transparency, and scientific rigor of assessment as process components that ultimately influence the reasonableness of appraisal. Accordingly, we stated 5 hypotheses:
The higher the degree of transparency, the higher the degree of reasonableness (in terms of the relevance of clinical, economic, and other ethical) decisionmaking criteria because this facilitates a better control of the decision makers. 9 Hypothesis 2 (participation À! reasonableness): The higher the degree of participation, the higher the degree of reasonableness because the higher the degree of participation, the better stakeholders and the covered population can ensure that the technology is appraised against criteria they consider reasonable. 9 Hypothesis 3 (scientific rigor À! reasonableness): The higher the degree of scientific rigor, the higher the degree of reasonableness because decision makers can draw upon better evidence regarding whether the criteria are met. 9 Hypothesis 4 (transparency À! scientific rigor): The higher the degree of transparency, the higher the degree of scientific rigor of assessment because the methodological quality can be better controlled by the scientific community. Hypothesis 5 (participation À! scientific rigor): The higher the degree of stakeholder participation, the higher the degree of scientific rigor of assessment. If more stakeholders participate in different stages of decision making, more evidence is identified and improvements of a weak evidence basis can be enforced more easily.
Development of a Structural Equation Model
To analyze the relationships between the components, an empirical method is needed that has several requirements. The components cannot be measured directly. For example, transparency is a concept that cannot be observed from documentation but can be considered as a latent construct. The hypotheses suggested multiple and interrelated dependence relationships. Thus, the method should capture the set of linkages between process components.
SEM techniques-a combination of factor and multiple regression analysis-are capable of measuring interrelationships between latent constructs. 35 SEM inherits several properties that differ from multivariate regression, which seem beneficial in our context. 36 In regression analysis, one dependent variable is typically explained by several independent variables. Multiple but nonhierarchical endogenous constructs (here: reasonableness and scientific rigor) would require specification of several regression models. Using SEM, this can be performed in 1 step. Multivariate regression does not easily allow the specification of the relationship between a latent construct and its observable indicators. Instead, the observable indicators that describe a latent construct would need to be combined into an aggregate score that may over-or underestimate the influence of single indicators. In SEM, the relevance of each indicator is determined in the model so that no bias occurs from arbitrary definition of latent construct scales. In addition, 1 branch of SEM offers estimation techniques that do not require distributional assumptions that we could not state reliably for most indicators.
We defined an SEM considering each component as a latent construct described by a set of observable indicators. For operationalization, we developed an Internet survey based on the framework of Rogowski and others 37 and a corresponding structured survey instrument for data collection. 20 The framework describes the stylized steps of a process from the point where a technology enters a health care market to diffusion into routine use. One question was stated per indicator in an online questionnaire (available from the authors upon demand). The SEM combines the linkages between constructs in the structural model and the relations between constructs and indicators in the measurement models (see Figure 1 ). All constructs were defined in the reflective mode, meaning that the causality is directed from the construct to the indicator. Table 1 describes all constructs and indicators.
Formally, the structural model can be written as
where b 11 and b 22 denote the path coefficients of the 2 exogenous constructs, transparency h 1 and participation h 2 , on the construct scientific rigor; b 12 , b 21 , and b 31 are the path coefficients of the constructs transparency, participation, and scientific rigor to the construct reasonableness h 3 ; and j 3 and j 4 represent the endogenous constructs' residuals. In the measurement models of equation (2), each indicator y ij of a construct h i , i = 1, . . ., 4 is a linear function of its loading l ij and the residual e ij, . The index j denotes the indicator y j of the construct h i , j = 1, . . ., k i . : : ð2Þ
Survey Instrument and Data
We conducted a retrospective cross-sectional survey on decisions made on health technologies in European Union (EU) member states and Organization for Economic Co-operation and Development (OECD) countries between 2006 and 2011.
Sampling of Observation Units
A decision was defined as an appraisal procedure to determine reimbursement of a primary third-party payer. We equally considered advisory and decisionmaking committees. While decision-making committees are in charge of making legally binding decisions, advisory committees make recommendations to a higher authority rather than decisions. 38 However, recommendations are frequently adopted without challenge. Each decision was identified by country, payer, deciding committee, technology, health condition, and further specifications (e.g., restrictions to patient subgroups). If decisions were made at a regional level, the instrument captured the geographical area.
Identification of Respondents
Experts within the field of HTA and economic evaluation who had observed or participated in decision processes were identified from the abstract books of 2 conferences: the HTA International (HTAi) meeting in 2010 in Dublin, Ireland, 39 and the congress of the International Health Economics Association in 2011 in Toronto, Canada. 40 Email addresses were identified via the membership directories, Google, and the PubMed database. Abstracts were screened by title and needed to relate to coverage, HTA, or economic evaluation. Participants' affiliations or abstract titles should indicate that experts could provide information for EU or OECD member countries. To obtain a balanced sample in terms of the countries represented, we applied a form of quota sampling. We distributed countries with more than 5 eligible abstracts into 2 waves, each with 5 respondents, as some were overrepresented because of hosting the congress (Ireland, Canada), having larger populations (United States), or having proceeded faster in the development of economic evaluation (United Kingdom). In total, 279 individuals were selected.
Internet Survey
Between June and October 2011, we invited respondents via email to participate in our Internet survey. It was implemented with EFS Survey Version 8.0 (Unipark GmbH, Hü rth, Germany). To limit the survey length, we restricted the number of decisions to 4. To minimize recall bias and to focus on recent decision making, we asked respondents for decisions made within the past 5 years. The invitation related to the abstract and contained information on the survey background. To increase survey uptake, nonresponders were reminded at least twice. Respondents could provide contact details of individuals whom they considered eligible for the survey. Accordingly, we invited 31 additional respondents referred from the initial contact. The survey procedure was piloted in May 2011. We assessed the comprehensibility of the questions, the technical implementation, and the procedure for contacting respondents among 9 experts of the EU project HIScreenDiag. To test for appropriate reaction of conference participants, we invited 12 HTAi participants not included in the main mailing. No ethics approval was requested as no patient-related data were collected. No external funding was obtained for conducting the survey.
Data
The survey retrieved 119 decisions from 40 experts in 15 countries, of which 97 observations were used for model estimation. The response rate was 23%. Another 18% of respondents replied that they did not know decisions or referred to other experts. For verifying each decision specified by respondents,
Structural model
Participation η2
Scientific rigor-η3
Number of types of participating stakeholders (y 21 )
Scientific rigor in assessment of effectiveness (y 31 )
Scientific rigor in assessment of cost/ cost-effectiveness (y 32 )
Transparency η1
Amount of information published during or after decision process (y 11 )
Reasonableness η4
Type of information provided (y 12 Table  2 for a definition). Data preparation was performed with SAS version 9.2 (SAS Institute, Cary, NC). We had to apply an algorithm to replace missing data because some respondents gave partial information. Four respondents did not specify a decision, and another 4 respondents provided data that only specified the decision object but no information about the thirdparty payer and deciding committee. Thus, the decision was not attributable. Another 7 observations were excluded in which more than 60% of questions were not answered. For 12 observations with missing values, we applied conditional mean imputation. We imputed the mean for the same decision-making institution or, if not represented, the country. If no data could be imputed, which was the case for 4 observations, SmartPLS (Hamburg University of Technology, Institute for Human Resource Management and Organizations, Hamburg, Germany) substituted the overall sample mean. Missing values were more prevalent at the end of the questionnaire. The summary statistics ( Table 2) include information on missing values per indicator.
Model Estimation and Evaluation
Two types of modeling techniques are available for SEM that depend on the optimization algorithm. 43 In partial least squares path modeling (PLS-PM), the share of the variance that is explained for the endogenous constructs by the SEM is maximized through a series of ordinary least squares regressions. In the covariance-based techniques (LISREL, AMOS), maximum likelihood estimators extract a set of model parameters so that the theoretical covariance matrix is as close as possible to the empirical covariance matrix.
We selected PLS-PM for several reasons: contrary to the covariance-based techniques of SEM, it allows model estimations with small sample sizes and without making distributional assumptions. 44, 45 It is suitable for exploration and prediction of effects at early stages in theoretical development. In contrast, covariance-based techniques are better suited for confirmatory analysis but require knowledge of parameter distributions and larger sample sizes. 43 If the sample size is large, covariance-based methods are preferable because of better parameter consistency and accuracy. If the focus is on prediction and theory development-as in our case-PLS-PM should be preferred. 43 For the underlying SEM, a feasibility test to assess whether plausible estimation measures can be obtained from the PLS-PM algorithm has been performed using data on decisions of newborn screening technologies. 46 For estimation, we used the SmartPLS version 2.0. 47 Through application of an iterative procedure, the PLS-PM algorithm calculates the path coefficients between the latent constructs and the scores of the constructs in the structural model and the weights and loadings of the manifest indicators in the measurement models in a sequence of ordinary least squares regressions. 44 The path weighting scheme was applied to calculate the inner weights in the iteration procedure. We assessed the model estimation against established reliability and validity measures for PLS-PM at the level of the measurement and structural model. 36, 44, 48 To obtain asymptotic t statistics, we applied a bootstrapping procedure with 5000 samples. In contrast to covariance-based approaches and regression analysis, assessing the model's overall goodness of fit is limited because a distribution-free variance is assumed. 48 
Sensitivity Analyses
We performed sensitivity analyses to assess influences from missing data, nonresponse bias, and nesting effects. Regarding missing data, we reestimated the model with the 85 complete observations. However, we used the imputed data set as the base case. Furthermore, we compared the data set with complete cases only with the imputed data set for nonrandom influences from the type of technology (pharmaceuticals v. others) and involvement of respondents in the decision (direct v. indirect) with the Fisher exact test. Regarding nonresponse bias, we assessed whether the proportion of survey respondents differed from the individuals who were contacted but did not respond to the survey by country. To analyze whether data were missing at random regarding the scope of decision, we further compared qualitatively whether the decisions that were excluded because of missing values differed by health condition and technology from those included in the data set. To account for potential nesting effects from the clustering of decisions by respondents, we randomly drew a reduced data set with 31 complete observations in which each respondent was represented just once. We compared reliability and validity of the SEM with the estimation of the full data set. Table 3 provides an overview of decisions by country, decision-making institution, and outcome. Spanish health authorities (23), the UK National Institute of Health and Clinical Excellence (NICE) (12) , the German Federal Joint Committee (FJC) (10) , and the Irish Health Service Executive (9) were most frequent. Although acceptance rates varied across institutions, half the decisions resulted in unrestricted coverage. The other decisions resulted about equally in restricted or no coverage. Table 4 provides an overview of the technologies and health conditions. Most decisions were made on prescribed medicines (47) , specialized inpatient curative care (16) , or therapeutic appliances (9) . Health conditions covered a wide range of the ICD-10. Some indications were more prevalent: cancer (25) , diseases of the circulatory system (16) , and endocrine, nutritional, and metabolic diseases (10) . Decisions covered different indications except for 7 responses on vaccines against human papillomavirus and a few technologies with 2 responses.
RESULTS
Descriptive Statistics
Summary statistics of indicators are presented in Table 2 . Clustering results by decision committees showed that processes were heterogeneous not only between countries but also for the same decision committees. Regarding nonresponse biases, we found that compared with our initial set of conference participants, some countries were overrepresented (Spain, Ireland, and United Kingdom), whereas others were underrepresented (Canada and United States) in the study sample. From the 7 observations that had to be excluded because of too many missing values, 5 decisions were on technologies other than pharmaceuticals.
Structural Equation Model Results
In compliance with the PLS-PM literature, we first provide reliability and validity measures for the measurement models before we present the results of the structural model. 36 The online appendix provides the values for all evaluation measures. Estimated path coefficients and indicator loadings are depicted in Figure 2 .
Measurement Models
Overall, the measurement model estimations were acceptable in terms of reliability and validity at the construct and indicator levels. Composite reliability is a measure between zero and 1 for reliability at the construct level. Accounting for nonequal indicator loadings, it assesses whether indicators consistently represent the same construct. Values for composite reliability for the constructs participation and transparency were greater than the critical value of 0.7 and at least 0.66 for the constructs reasonableness and scientific rigor. A value of 0.6 is acceptable in the early research stages. 48 For reliability at the indicator level, the indicators' variance that was explained by the construct varied. This information was obtained from the indicator loadings, which denote the correlation with the construct. For the constructs participation, transparency, and scientific rigor, indicators were highly correlated with corresponding constructs except for the indicator ''number of types of stakeholders participating in voting.'' Its value was below zero, which we did not hypothesize, and its absolute value was small, indicating a lack of indicator reliability. In the reasonableness construct, the indicators' correlations with the construct varied. The indicator that describes the relevance of cost-effectiveness as a decision criterion was correlated highest. Some 74% of the variance was explained by this construct. The smallest correlation was obtained for the criterion ''severity of the disease'' (l 46 = 0.28). Validity is assessed by convergent and discriminant validity. Convergent validity describes whether the set of indicators uniquely represents the underlying construct. The average variance extracted (AVE) measures the variance of the indicators of the reflective construct relative to the total amount of variance, including the measurement error's variance. The AVE was greater than the suggested threshold of 0.5 for the constructs transparency (AVE(h 1 ) = 0.9), participation (AVE(h 2 ) = 0.53), and scientific rigor (AVE(h 3 ) = 0.5) but not for the reasonableness construct (AVE(h 4 ) = 0.27). Two measures were used to evaluate discriminant validity. They appraise whether the constructs are sufficiently distinct from each other. The Fornell-Larcker criterion provides a comparison of the AVE of a latent variable with the squared correlations between the construct and any other construct. For all constructs, the AVE was larger than any other squared correlation, suggesting that the indicator sets are sufficiently related to the construct. Second, the indicators' cross-loadings with other constructs were compared. These were at maximum at the assigned construct for all indicators except for the ''number of stakeholders participating in voting'' (y 22 ) of the participation construct.
Structural Model
At structural model level, 3 of the 5 paths had the expected sign and were significant. The degree of reasonableness was significantly influenced by the degree of participation and scientific rigor of assessment, which supported hypotheses 2 and 3. Their path coefficients, which can be interpreted as standardized b coefficients, were significant with P values smaller than 0.001. The effect of scientific rigor on the degree of reasonableness was nearly twice as large (b 31 = 0.49) as that of participation (b 21 = 0.29). Furthermore, the results supported hypothesis 5 as the scientific rigor was significantly influenced by the degree of participation (P\0.001). Hypotheses 1 and 4 were not supported as the degree of transparency had a nonsignificant effect on the endogenous constructs.
The determination coefficient R 2 -analogous to multiple regression-reflected that the share of the variance explained was 44.3% for the construct reasonableness and 13.8% for the construct scientific rigor. The goodness-of-fit index, which is defined here by the geometric mean of the average communality and the model's average R 2 , was 0.37. 49 It measures the average of all the squared correlations between each indicator and the corresponding latent construct. We consider this value sufficiently high because of the high contribution of R 2 of the reasonableness construct and the value of the geometric mean of the communality (0.468). 45 However, the goodness of fit of PLS models has to be handled with caution because it includes R 2 for which acceptable values depend on the research context, and thus no single consented threshold exists. 48 The value of the average redundancy that measures the portion of the variability of the indicators connected to an endogenous construct explained by the latent construct directly connected to the block was 0.057. 45 Measures of the effect size f 2 revealed that the exogenous construct participation h 2 weakly contributed to the explanation of both endogenous constructs (h 3 , h 4 ). F 2 values for the construct transparency indicated that it did not contribute to an explanation of the endogenous constructs. Sensitivity analyses showed that the model results did not change fundamentally if the data set was restricted to the 85 observations without missing values and if only 1 observation from each respondent was used to avoid nesting effects. Furthermore, no significant difference between observations regarding missing values was identified depending on the type of technology and respondents' involvement decisions.
DISCUSSION
In both the ethical and the economic literature, theoretical considerations about decision processes have been based on the assumption that more assessment, transparency, and participation have a positive impact on the reasonableness of decision criteria. This is the first study that investigates this assumption with SEM methods.
Five hypotheses on the relation of the constructs transparency, participation, and scientific rigor on one another and on the construct reasonableness were specified, of which 3 were significant. According to the model, the degree of stakeholder participation and the scientific rigor of assessment positively influence the decisions' degree of reasonableness. The effect of the amount of released information was not statistically significant.
The scientific rigor of assessment had the highest positive association with our construct of reasonable decision making. This indicates that a sound evidence base may not only disclose relevant data on a health technology but also promote the application of reasonable appraisal criteria. Although this has been a frequently stated claim, our estimation confirms this notion. 50 Stakeholder participation displayed the second highest positive association with the degree of reasonableness. Strong stakeholder involvement may facilitate that singular interests are balanced and criteria that can be weighed against existing evidence play a higher role in decision making. This empirical result strengthens Friedman's criticism of the ''accountability for reasonableness'' framework that more participation than just a mechanism of appeal would be desirable to achieve legitimate and fair decisions about health care resources. 14 The positive association of the degree of reasonableness and the 2 components of scientific rigor and participation can also be seen as a first empirical confirmation of relations assumed in the ''accountability for reasonableness'' framework 13 as well as the economic theory of the fourth hurdle. 9 Our results further suggest that transparency matters less for making reasonable decisions, particularly if there is a sound scientific evidence base and sufficient possibilities for participation. Even if promoting transparency is a frequent claim in discussions about decision making, our estimation suggests that-contrary to our hypotheses-transparency may not be influential for achieving high levels of scientific rigor and for promoting reasonableness. Nevertheless, a high degree of transparency is likely to be beneficial for other reasons: to ensure consistency and legality of value judgments, to inform involved stakeholders about the coverage status of the technology, and to foster possibilities for participation. 50, 51 This corresponds with the role of transparency in rulings of social courts: according to Syrrett, 52 the primary function of transparency in juridical review was to facilitate meaningful stakeholder participation rather than to be a value in itself.
Participation
Scientific rigor
The indicator loadings of the reasonableness construct differed in size and need further interpretation. If the correlation of a criterion is low, this does not mean that it was not considered relevant for appraisal. Instead, it may not have been a suitable indicator for the degree of reasonableness. Accordingly, in processes where the criteria cost-effectiveness, effectiveness beyond health benefit, and budget impact-indicators with high loadings-are considered, this is likely to reflect reasonable decision making. The reason for the low correlation with the relevance of effectiveness in terms of the health gain (0.31) could be that it had little discriminative power: 84% of respondents stated that effectiveness was relevant. Thus, it appears not to be meaningful to explain the construct's variance. Overall, the AVE of this construct was low (27%). Considering the multitude of health system influences that we neglected, this value can still be considered acceptable.
Limitations
This study has several limitations. First, even if the model suggests causal relationships, these are still of an explorative nature because of the novelty of the research approach. This is consistent with the use of PLS modeling techniques, which are better suited for exploration and extension of existing theories than for theory confirmation. Also, the retrospective study design limits our interpretations. Causality is best established by means of prospective experimental studies, which was not possible in this research context. As in all retrospective observational studies, unmeasured constructs may have influenced the coverage decision processes.
Most studies collected data by extracting decision documentation, which restricts the analysis to welldocumented decision processes and may be subject to publication bias. Our approach attempted to collect general indicators of our constructs, which can also be collected for less documented and rigorous decision-making processes. 17 However, using common categories for many processes also limits the level of detail that can be assessed. For example, variation in the level of influence from the stakeholder types was not mapped. We asked for types of interest groups but not the number of institutions involved for each type, which may have conflicting interests. Nevertheless, the reliability and validity measures suggest that the components' variation is captured sufficiently. Although highly correlated, we did not model a link between participation and transparency as the literature does not support a clear causal relationship (i.e., into one direction) between these components. An estimation in which a link going from transparency to participation was inserted showed that the path coefficient between transparency and participation was positive and significant. However, the original SEM estimates did not change in terms of sign and significance.
The estimation is based on a small sample size. We accounted for this by selecting PLS-PM and complying with a rule of thumb for the minimum sample size. 48 Some decision makers are overrepresented, in particular, decisions from Spain, the UK NICE, or the German FJC. Obtaining responses from countries with less HTA activity and looser regulations is difficult as there are fewer experts in the field. Nevertheless, the data set can be regarded as representative in terms of technologies and health conditions represented, especially relating to cancer and diseases of the circulatory system. 4 Most decision makers have focused on coverage of pharmaceuticals that are sufficiently represented. However, our data suggest that also other technologies are increasingly the subject of formal procedures. Regarding nonresponse bias, 5 of 7 decisions that were excluded because of too many missing values dealt with screening, vaccination, or rehabilitation. Given that these may be technologies with less structured processes, they may be underrepresented in our sample.
The distribution of countries that were represented reflects major OCED/EU member countries. Decision making of new EU accession countries is represented to a limited extent because responses only from Poland were obtained.
The sensitivity analyses demonstrated that influences from nonresponse and nesting effects were small. Nevertheless, a multilevel approach would be preferable to correctly identify variation at country, decision maker, and decision levels. If more data were available, unobserved heterogeneity could have been addressed to identify clusters of decision making. 53 
Policy Implications
Transparency, participation, and scientific rigor are procedural criteria for coverage decision processes frequently called for in the literature and required by social law. In case tradeoffs between these exist, this study suggests that, first, rigorous assessment of the evidence and, second, sufficient stakeholder involvement should be promoted to achieve reasonable coverage decisions.
CONCLUSIONS
This is the first study that uses PLS modeling methods to empirically analyze relations between characteristics of decision processes and the reasonableness of substantive criteria used in coverage decisions. Rigorous assessment and intense stakeholder participation appeared effective in promoting reasonable decision making, whereas the influence of transparency was not significant. A sound evidence base seems most important as the degree of scientific rigor of assessment had the strongest effect. Further theoretical and empirical research is necessary to extend the theoretical basis of our hypotheses on the factors influencing decisions and to confirm our results.
